Genelux (NASDAQ:GNLX) Upgraded by Wall Street Zen to “Hold” Rating

Wall Street Zen upgraded shares of Genelux (NASDAQ:GNLXFree Report) from a sell rating to a hold rating in a research note released on Saturday morning.

Other equities research analysts have also issued research reports about the stock. HC Wainwright reaffirmed a “buy” rating and issued a $30.00 target price on shares of Genelux in a report on Monday, March 31st. Benchmark decreased their price objective on shares of Genelux from $25.00 to $23.00 and set a “speculative buy” rating on the stock in a research note on Thursday, May 8th. One research analyst has rated the stock with a hold rating, four have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, Genelux presently has an average rating of “Buy” and a consensus price target of $17.75.

View Our Latest Stock Analysis on Genelux

Genelux Stock Performance

NASDAQ:GNLX opened at $3.06 on Friday. The company has a 50-day moving average of $2.59 and a 200-day moving average of $3.07. Genelux has a 52 week low of $1.60 and a 52 week high of $5.89. The company has a market capitalization of $115.47 million, a price-to-earnings ratio of -3.22 and a beta of -0.49.

Genelux (NASDAQ:GNLXGet Free Report) last released its quarterly earnings data on Thursday, May 8th. The company reported ($0.21) earnings per share for the quarter, beating the consensus estimate of ($0.24) by $0.03. Sell-side analysts forecast that Genelux will post -0.88 EPS for the current year.

Hedge Funds Weigh In On Genelux

A number of institutional investors have recently modified their holdings of the stock. Virtu Financial LLC bought a new stake in shares of Genelux during the fourth quarter valued at approximately $25,000. Advisor Resource Council bought a new position in Genelux in the 1st quarter valued at $34,000. Apollon Wealth Management LLC increased its stake in shares of Genelux by 20.4% in the 4th quarter. Apollon Wealth Management LLC now owns 16,863 shares of the company’s stock valued at $40,000 after buying an additional 2,857 shares during the period. Raymond James Financial Inc. acquired a new position in shares of Genelux during the fourth quarter valued at $41,000. Finally, Liberty Wealth Management LLC bought a new position in Genelux in the first quarter valued at about $45,000. 37.33% of the stock is owned by institutional investors.

About Genelux

(Get Free Report)

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer.

Featured Articles

Analyst Recommendations for Genelux (NASDAQ:GNLX)

Receive News & Ratings for Genelux Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genelux and related companies with MarketBeat.com's FREE daily email newsletter.